Anson Funds
Anson Funds is an investment management firm established in 2003 and headquartered in Dallas, Texas, with an additional office in Toronto, Canada. The firm manages over $1.5 billion in assets, focusing on publicly traded equity and debt securities globally. Anson Funds employs a variety of investment strategies, including long/short equity, event-driven, distressed situations, capital structure arbitrage, and relative value approaches, often adopting a long bias toward public equities and fixed-income markets. The firm aims to deliver net-of-fees performance characterized by low volatility and low correlations to broader market indexes. Anson Funds has gained recognition in the financial industry, receiving a Top 10 Hedge Fund ranking by Barclay Managed Fund from 2018 to 2020, and has been featured in prominent publications such as Barron’s and Bloomberg. Its flagship fund, launched in 2007, is complemented by other hedge funds focusing on real estate and tactical equity strategies.
5 past transactions
InterRent REIT
Post in 2025
InterRent REIT is a real estate investment trust focused on enhancing Unitholder value through the acquisition and ownership of multi-residential properties across Canada. The organization aims to expand its portfolio in markets with stable vacancies and sufficient available units to facilitate effective management. InterRent's primary goals include providing Unitholders with stable and growing cash distributions from a diversified property portfolio, enhancing asset value through active management, and increasing distributable income via strategic acquisitions. Revenue is generated from rental income as well as ancillary services such as parking and laundry. The company emphasizes a conservative payout ratio to maintain a healthy balance sheet while pursuing growth.
NRx Pharmaceuticals
Post in 2025
NRx Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing innovative therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company aims to address critical health challenges by researching and scaling solutions for conditions that often remain untreated. Notably, NRx has announced the commercialization of ZYESAMI (Aviptadil), which targets COVID-related respiratory failure. Additionally, the company is advancing NRX-100/101, a pioneering sequential drug regimen designed for the treatment of bipolar depression in patients experiencing acute suicidal ideation and behavior. In a significant development, NRx was granted exclusive worldwide rights to develop and market the BriLife COVID vaccine by the Government of Israel, further expanding its portfolio in the fight against serious health threats.
Lionsgate
Post in 2024
Lionsgate is a global content company that develops, produces, and distributes feature films and television programs for audiences worldwide, with a portfolio that includes digital content and interactive ventures. The company operates through three segments: Motion Picture, which handles feature film development, production, and worldwide distribution; Television Production, which develops and distributes television series, movies, and non-fiction programming; and Media Networks, which distributes Starz-branded services and manages streaming and related media assets. Lionsgate maintains a large library of film and television titles and engages in home entertainment, licensing, and promotional activities. It also licenses Starz original productions and related programming to STARZ networks and international platforms, and distributes content through packaged media and digital channels, positioning itself as a diversified content powerhouse across traditional and on-demand formats.
NRx Pharmaceuticals
Post in 2024
NRx Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing innovative therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company aims to address critical health challenges by researching and scaling solutions for conditions that often remain untreated. Notably, NRx has announced the commercialization of ZYESAMI (Aviptadil), which targets COVID-related respiratory failure. Additionally, the company is advancing NRX-100/101, a pioneering sequential drug regimen designed for the treatment of bipolar depression in patients experiencing acute suicidal ideation and behavior. In a significant development, NRx was granted exclusive worldwide rights to develop and market the BriLife COVID vaccine by the Government of Israel, further expanding its portfolio in the fight against serious health threats.
View
Post in 2023
View, Inc., established in 2006 and headquartered in Milpitas, California, specializes in designing and manufacturing intelligent glass systems for various sectors, including workplace, healthcare, education, and hospitality. The company's flagship product, View Smart Windows, employs AI to automatically adjust in response to sunlight, enhancing natural light access and occupant experience, while minimizing heat and glare, and reducing energy consumption. Each View installation also includes a cloud-connected smart building platform, enabling further building optimization. With operations in the U.S. and internationally, View has improved over 90 million square feet of buildings, ranging from offices to multifamily residences.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.